🔗 Visit the ClinicalTrials.gov page for NCT02409342
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Checkpoint inhibitors in lung cancer: latest developments and clinical potential. | Ther Adv Med Oncol | 2016 | 0.96 |
| 2 | Advances in immunotherapy for treatment of lung cancer. | Cancer Biol Med | 2015 | 0.95 |
| 3 | Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. | Invest New Drugs | 2016 | 0.80 |
| 4 | Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting. | Ann Transl Med | 2016 | 0.77 |
| 5 | Lung cancer in 2015: Bypassing checkpoints, overcoming resistance, and honing in on new targets. | Nat Rev Clin Oncol | 2015 | 0.76 |
| 6 | Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer? | Transl Lung Cancer Res | 2016 | 0.75 |
| 7 | Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment. | Onco Targets Ther | 2016 | 0.75 |